Robeco Institutional Asset Management B.V. Buys 16,706 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Robeco Institutional Asset Management B.V. boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.3% in the third quarter, Holdings Channel.com reports. The firm owned 113,074 shares of the biopharmaceutical company’s stock after acquiring an additional 16,706 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Alnylam Pharmaceuticals were worth $51,562,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Longboard Asset Management LP bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth about $228,000. Park Place Capital Corp bought a new position in Alnylam Pharmaceuticals in the third quarter valued at $57,000. Earned Wealth Advisors LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $268,000. Asset Management One Co. Ltd. lifted its position in Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 69,610 shares of the biopharmaceutical company’s stock worth $31,742,000 after buying an additional 300 shares in the last quarter. Finally, Western Financial Corp CA acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $1,242,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $422.50 on Thursday. The stock has a market cap of $55.82 billion, a price-to-earnings ratio of 1,760.42 and a beta of 0.32. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company’s fifty day moving average is $427.88 and its 200 day moving average is $419.43.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,517,119.43. This represents a 13.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 37,778 shares of company stock worth $17,096,988. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ALNY has been the topic of a number of recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. The Goldman Sachs Group boosted their price target on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a report on Monday, October 6th. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Truist Financial upped their price target on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $484.42.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.